induce expression of the pump. As we are unable to directly measure epoxomicin uptake we utilized another P-gP substrate to determine if drug efflux is altered in KMS11R cells. Doxorubicin is an established substrate for P-gP and it can be easily measured in the cell because it fluoresces red. We compared the fluorescence of KMS11 and KMS11R cells treated with various concentrations of doxorubicin for 24 h. No differences in background fluorescence were observed and both cell lines could take up doxorubicin in a dose-dependent fashion (Figure 2b) . However, the uptake observed was 3-5 fold lower in the resistant line. In addition, KMS11R cells are significantly resistant to doxorubicin-induced cell death (not shown).
Finally, we determined the role of P-gP in the acquired resistance to epoxomicin by observing the effects of inhibiting PgP function with verapamil. Verapamil had no effect on the viability of either cell line nor did it alter the sensitivity of KMS11 cells to epoxomicin (Figure 3a) or doxorubicin (not shown). In contrast verapamil resensitized KMS11R to both drugs ( Figure 3a and not shown). FACS analysis of cells treated with doxorubicin and verapamil revealed that the addition of verapamil to the KMS11R cells resulted in an increase in red fluorescence in doxorubicin-treated cells (Figure 3b ).
Given the promise of bortezomib it is not surprising that other proteasome inhibitors that are either irreversible and/or inhibit the other activities of the proteasome are currently being tested in the clinic. As proteasome inhibitors become more commonly used in newly diagnosed diseases it will be important to understand mechanisms of acquired resistance to this class of agents. In addition, we will need to know how acquired resistance to proteasome inhibitors alter the response to other therapeutics used to treat myeloma patients.
Acquired expression of P-gP has been observed in myeloma patients and cell lines. P-gP is rarely seen in newly diagnosed patients, however, increased expression was observed in cells from approximately 75% of patients treated with vincristine, doxorubicin and dexamethasone. 6 We observed that P-gP is expressed and the P-gP inhibitor verapimil sensitizes KMS11R to epoxomicin. These data suggest that the acquired resistance observed was the result of P-gP expression. This is the first report to demonstrate the acquisition of P-gP with a proteasome inhibitor. Although it is possible that the induction of P-gP could be the result of inhibition of protein turnover, this does not appear to be a likely mechanism. First epoxomicin does not acutely induce P-gP ( Figure 2 ). More importantly we also observe increased expression of the MDR mRNA in these cells (not shown). Thus the mechanism is likely to be due to increased gene expression possibly because of gene amplification. This remains to be determined.
Finally, our data suggest that carfilzomib could be ineffective in the treatment of P-gP-positive myeloma. Consistent with this possibility, a recent study demonstrated that the P-gP-positive cell line, RPMI8226-Dox40, is resistant to carfilzomib; however, they can be sensitized by co-treatment with verapamil. 7 Unfortunately such resensitization of cells to P-gP substrates has not proven to be effective clinically. 6, 8 Several agents that inhibit drug efflux have been tested and either proven to be too toxic or had little effect on efficacy. In addition to confirming that epoxomicin-based compounds may be subject to this type of resistance mechanism we demonstrated that they can initiate resistance in this fashion. Therefore careful consideration of the use of these compounds both as single agents and in combination therapies will be needed to assure both efficacy of this therapy as well as subsequent treatment regimens.
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Mutations of ASXL1 gene in myeloproliferative neoplasms
Leukemia ( Leukemogenesis is a complex process resulting from the alterations of many genes that perturb the processes leading from a hematopoietic stem cell to a differentiated blood cell. The ASXL1 (additional sex combs like 1) gene is located in the chromosomal region 20q11 and may be affected in hematologic malignancies.
1 ASXL1 belongs to a family of three identified members that encode poorly characterized proteins regulating chromatin remodeling.
The ASXL proteins contain a C-terminal PHD (plant homeodomain) finger and belong to polycomb and mixed lineage leukemia/trithorax chromatin modifier complexes. We have recently shown that ASXL1 is mutated in roughly 10% of myelodysplastic syndromes (MDS) and 40% of chronic myelomonocytic leukemias; 2 mutations were mostly heterozygous, frameshifts, and located in exon 12. The predicted truncated protein would lack its PHD domain, thus compromising the function of the associated chromatin modifiers. In contrast, we did not find mutations of ASXL2 in MDSs and chronic myelomonocytic leukemias (N Carbuccia and MJ Mozziconacci, unpublished). By using high resolution array-comparative genomic hybridization, we also detected a heterozygous loss of ASXL1 in one MDS case. 2 These observations suggest that ASXL1 haploinsufficiency plays a role in leukemogenesis.
To determine whether ASXL1 could be involved in other types of myeloid diseases, we studied the ASXL1 gene in 64 myeloproliferative neoplasms (MPNs). Our series comprised 10 cases of polycythemia vera, 35 cases of essential thrombocythemia (ET), 10 cases of primary myelofibrosis (PMF), 1 case of prefibrotic PMF, 5 MPNs at blast phase and 3 unclassifiable MPNs. We also searched for mutations in 12 non-MPN cases comprising 7 secondary thrombocytosis and 5 secondary erythrocytosis. All patients signed an informed consent and the study was approved by our ethical committee. We searched for ASXL1 deletions by array-comparative genomic hybridization on 28 samples by using high-density oligonucleotide microarrays (Hu-244A, Agilent Technologies, Massy, France), as previously described.
3 ASXL1 mutations were searched by DNA sequencing, as described. 2 We also searched for mutations of JAK2 (V617F) and TET2 (all exons). TET2 mutations have been found in 5-20% of MPN 4, 5 and in other myeloid diseases, [6] [7] [8] and may be predicted to affect gene regulation.
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TET2 missense mutations were considered when located in conserved regions, spanning amino acids 1134-1444 and 1842-1921. 4 We did not find any deletion of ASXL1 or TET2 by arraycomparative genomic hybridization (not shown). One deletion at 1p31, comprising NFIA, has been reported previously. 10 We found heterozygous TET2 frameshift mutations in 4 out of the 64 MPN cases (6.2%), 2 ET and 2 PMF (Table 1) . We found heterozygous frameshift mutations of ASXL1 in 5 cases (7.8%) including 1 ET out of 35, 3 PMF out of 10 (1 was in accelerated phase) and 1 acute myeloid leukemia (AML) post-ET (Figures 1  and 2 ). We also found three cases of substitutions (shown with footnote 'a' in Table 1 ) that we did not take into account because they could represent polymorphisms. None of the five ASXL1-mutated cases carried a JAK2 V617F mutation. Only one (a PMF) of these five cases was also mutated for TET2. The four other cases did not have a TET2 mutation but two of them showed an abnormal karyotype; case HD-0535 showed a t(3;12) with upregulation of HMGA2.
11 Table 1 shows summarized results on the cases with a sequence variation in either TET2 or ASXL1 (the remaining cases did not show variations of TET2 or ASXL1 deduced amino acid sequences).
We analyzed the same sequences in DNA extracted from CD34-purified cells of three patients with ASXL1 and/or TET2 mutation in their blood cell DNA (HD-0496, HD-0536 and HD-0540). The same ASXL1 and TET2 mutations were detected in the corresponding CD34 DNA. This is in agreement with what is known of the physiopathology of MPNs and suggests that ASXL1 mutations occur early during disease evolution.
Our study shows that several potential tumor suppressors may be inactivated in MPNs, especially in PMF. However, larger studies are required to better define the prevalence and prognostic impact of ASXL1 mutations, and their association with TET2 and JAK2 mutations. It further suggests that cumulated haploinsufficiency may play a role in leukemogenesis; however, truncated proteins may also have a dominant negative effect, and inactivation may also occur though epigenetic regulation. A first hypothesis is that TET2 and ASXL1 alterations (single or combined) lead to an increase in the program of self-renewal in Letters to the Editor MPN progenitors through modifications of DNA and histone regulatory marks. Mutations of TET2 and ASXL1 are also found in MDSs, 2, 3, 6, 7 suggesting that additional alterations are responsible for the differences between the two types of chronic myeloid disease. JAK2 V617F is one of these, but in the JAK2-negative cases they are unknown. Upregulation of HMGA2, which also controls chromatin structure, may participate. 11, 12 In our study, ASXL1 and JAK2 V617F mutations were mutually exclusive. Thus, a second hypothesis is that ASXL1 plays the role of JAK2 in MPNs non-mutated for JAK2. However, our series is too small to allow any conclusion.
Together with the recent report on UTX mutations, 13 our study further suggests that some modifications of epigenetic status in tumor cells are consequences of mutations in specific genes. 
